Zoono Newsletter, page-2

Thank you for posting Heyline.

Several ‘usual suspects’ have once more provided their predictable and repetitive statements regarding the Q4 release. Thank you for pointing out what is not going well. We have read your comments on the Quarterly Activities thread. No need to post again. Thank you.

As a forward-looking genuine holder, there is also a lot to like. IMO.

If you haven’t already, please read through the Zoono Newsletter (posted by Heyline) and think about what has actually been achieved during the very difficult Global COVID lock down, in setting up the distribution networks, with more on the way. We should also appreciate that the rigorous evidence-based research conducted by Zoono does take months to complete. But to know that Zoono continues to test and collect data regarding Zoono’s efficacy is also extremely positive. To be in a position to publish that: Results confirm that Zoono has also successfully tested against the Delta variant with a non-toxic, environmentally-friendly antimicrobial product that is available across the globe is, I think, quite powerful.

Try to reflect on what is working: What is going well?

Zoono has announced several new sales and distribution agreements in France, Russia, China and India that are now in place.

More specifically:
Selling to several French multinational customers.
Three new distribution agreements in China.
A new distributor in India placed a large 100,000-litre order.
Sales have been particularly strong in the public sector” in Russia.

New business opportunities: a lot to like.

To illustrate, Zoono describes advancements in “mould remediation” with a partner in South Africa. This activity aims to prevent black mould growing on cardboard packaging - another potential huge sector (food transport/preservation)

Moreover, Zoono UK has commenced a strategic partnership with a third party in order to develop “a unique delivery system” for its Zoono Z-71 microbe shield, specifically utilising the existing air conditioning infrastructure in large buildings. As we know, Delta is very virulent with internal airborne transmission being the prevalent means of infection. Infections in hotel quarantine via air transmission is also well-documented. This, IMO, is another huge potential business opportunity, globally.
But it will take time, with further research, testing, validation and commercialisation necessary. Which steps have already been met?

So, a patient play is required. IMO. GLTAH.